Last reviewed · How we verify

Sabril® — Competitive Intelligence Brief

Sabril® (Sabril®) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GABA transaminase inhibitor. Area: Neurology.

marketed GABA transaminase inhibitor GABA transaminase (ABAT) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Sabril® (Sabril®) — Lundbeck LLC. Sabril (vigabatrin) irreversibly inhibits GABA transaminase, the enzyme that breaks down the neurotransmitter GABA, thereby increasing GABA levels in the brain.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sabril® TARGET Sabril® Lundbeck LLC marketed GABA transaminase inhibitor GABA transaminase (ABAT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GABA transaminase inhibitor class)

  1. Lundbeck LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sabril® — Competitive Intelligence Brief. https://druglandscape.com/ci/sabril. Accessed 2026-05-21.

Build your own brief

Pick any drug + add comparators: